INCYTE CORPORATION Debt Conversion, Converted Instrument, Amount
INCYTE CORPORATION (INCY) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2023-02-07
- INCYTE CORPORATION debt conversion, converted instrument, amount for the quarter ending 2020-12-31 was $12.01M.
- INCYTE CORPORATION debt conversion, converted instrument, amount for the quarter ending 2020-09-30 was $6.83M.
- INCYTE CORPORATION debt conversion, converted instrument, amount for the quarter ending 2016-03-31 was $4.00K.
- INCYTE CORPORATION debt conversion, converted instrument, amount for fiscal 2022 was $0.00.
- INCYTE CORPORATION debt conversion, converted instrument, amount for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- INCYTE CORPORATION debt conversion, converted instrument, amount for fiscal 2020 was $19.00M.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-07 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-02-07 | |||
| 2020-12-31 | $12.01M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $18.84M derived: sum of 2 quarters · filed 2023-02-07 | $19.00M 10-K · filed 2023-02-07 | |
| 2020-09-30 | $6.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $6.99M 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $162.00K 10-Q · filed 2021-08-03 | |||
| 2016-03-31 | $4.00K 10-Q · filed 2016-05-09 | |||
| 2015-09-30 | $88.96M 10-Q · filed 2015-11-03 | |||
| 2014-09-30 | $4.66M 10-Q · filed 2015-11-03 | |||
| 2013-06-30 | $118.59M 10-Q · filed 2013-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |